Posted on 4/6/17
Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics and Charles River Laboratories International, Inc. (NYSE: CRL) today launched a multi-year strategic partnership to advance new programs spanning . . .
Posted on 4/5/17
Boston Children's Hospital Awarded John M. Eisenberg Award for Leading the I-PASS Study Group
The I-PASS Study Group based out of Boston Children's Hospital has been named the recipient of the 2016 John M. Eisenberg Award for Innovation in Patient . . .
Posted on 4/5/17
Blueprint Medicines Closes Public Offering
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its . . .
Posted on 4/4/17
Biogen's Valuation Is Compelling
In spite of share price performing in line with the peers and SPX market over the last months, I think the strengths and opportunities of Biogen . . .
Posted on 4/4/17
Palmier Foundation Partners with Boston Center
The Palmier Foundation is partnering with the Boston Center for Oral Health to provide those without adequate dental insurance with high-quality dental care. To date, The . . .
Posted on 4/3/17
Boston Scientific (BSX) Acquires Symetis SA - Slideshow
The following slide deck was published by Boston Scientific Corporation in conjunction with this event. 19READ FULL ARTICLE HERE
Posted on 4/3/17
Cara Therapeutics Is Scratching the Itch for Promising Biotechs
Micro-cap biotech Cara Therapeutics (NASDAQ:CARA) reported another in a string of positive trial results for its pain and itching drug, CR845. As the risk of failure . . .
Posted on 4/3/17
AVEO Closes Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise . . .
Posted on 3/31/17
Boston Scientific: Symetis Acquisition
Quick TakeMedical technology company Boston Scientific (BSX) has announced an agreement to acquire aortic valve medical device maker Symetis for $435 million in an all cash . . .
Posted on 3/31/17
Should Investors Worry About Bristol-Myers Squibb's Recent Setbacks?
A year ago, large-cap drugmaker Bristol-Myers Squibb (NYSE:BMY) was in the extraordinary position of having what many considered the best immuno-oncology franchise in the industry. But . . .
Posted on 3/31/17
Spero Therapeutics Receives $6.8 Million Award from CARB-X
Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced today that it has been awarded up to $6.8 . . .
Posted on 3/31/17
Entasis Therapeutics Announces Partnership with CARB-X
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced that it has entered into a partnership . . .
Posted on 3/31/17
Lantheus Announces Refinancing of its Debt Facility
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc., today announced the closing of a new $275 million term loan . . .
Posted on 3/31/17
Dicerna Scores $70M
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi)
Posted on 3/30/17
Sarepta Therapeutics Adds Kenneth Fischbeck and Matthew Wood to Strategic and Scientific Advisory Board
CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics . . .
Posted on 3/30/17
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced . . .
Posted on 3/30/17
Juniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary Event
Juniper Pharmaceuticals (Nasdaq: JNP) a women's health therapeutics company, today announced that it has been recognized as one of greater Boston's 15 companies with the most . . .
Posted on 3/30/17
Blueprint Medicines Prices Stock Offering
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an . . .
Posted on 3/30/17
Warp Drive Bio Forms Technology Alliance with GSK
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Warp Drive Bio, Inc., a life sciences company developing therapeutics that exploit the molecules and mechanisms of nature, announced today a collaboration with GSK, . . .
Posted on 3/30/17
Bicycle Therapeutics is Named Winner of Business Weekly’s Disruptive Technology Award 2017
CAMBRIDGE, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, . . .
Posted on 3/29/17
AVEO Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. . . .
Posted on 3/29/17
AVEO Prices $15.0 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price . . .
Posted on 3/28/17
T2 Biosystems: It Will Get Really Ugly Before It Gets Any Better
Another IPO FlopT2 Biosystems (NASDAQ:TTOO) is a classic IPO flop. At its Aug-2014 IPO, the medical diagnostic company offered 5.2 million shares with a price tag . . .
Posted on 3/28/17
Teva: Outstanding Buying Opportunity Ahead
ThesisAllergan (NYSE:AGN) will have the ability to sell 100M of Teva Pharmaceutical's (NYSE:TEVA) shares in August. Allergan acquired the shares when it sold Actavis Generics to . . .
Posted on 3/28/17
Advanced Radiology Consultants Recognized for Physician Marketing
Advanced Radiology Consultants, a leading provider of medical imaging in Connecticut, has been chosen by members of the Radiology Business Management Association (RBMA) as the recipient . . .
Boston
